Retatrutide Receptor Research
Last Updated: September 2026An annotated review of third-party molecular and cell-assay literature describing reported activity at GIP, GLP-1, and glucagon receptors.
Three reported receptor targets
The cited discovery paper characterizes LY3437943, the development identifier associated with retatrutide, using engineered cell systems expressing individual human receptors. The receptor cards below summarize that experimental target map.
GIP receptor
Reported as one of the molecule's agonist targets in human-receptor cell assays. The publication evaluates signalling after controlled exposure within its own assay system.
GLP-1 receptor
Reported as a second agonist target. Results are interpreted against reference ligands and the receptor-expression conditions stated by the authors.
Glucagon receptor
Reported as the third agonist target. Its inclusion distinguishes the published three-receptor profile from dual-receptor designs.
How the receptor findings were measured
The primary source reports cAMP accumulation in HEK-293 cell lines engineered to express one human receptor at a time. This separates receptor-specific signalling in the assay while keeping the conclusions tied to the authors' cell model.
cAMP accumulation
Cyclic adenosine monophosphate is a second messenger measured downstream of receptor activation. A concentration-response curve shows how the measured signal changes across the concentrations tested in that experiment.
Single-receptor cell lines
Each engineered cell line expresses a defined receptor. That design helps attribute the recorded response to GIPR, GLP-1R, or GCGR within the experimental system.
Reference ligands
Responses are compared with receptor-specific reference ligands selected by the authors. Those controls define the comparison inside the published assay.
Assay conditions
Cell background, receptor density, incubation time, reagents, and signal normalization can change reported potency and response values. Cross-paper comparisons require the complete methods.
Primary literature used here
- Coskun et al. (2022), DOI source — receptor characterization, human-receptor cell models, and cAMP assay methods.